[go: up one dir, main page]

WO2025168209A1 - Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation - Google Patents

Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation

Info

Publication number
WO2025168209A1
WO2025168209A1 PCT/EP2024/053112 EP2024053112W WO2025168209A1 WO 2025168209 A1 WO2025168209 A1 WO 2025168209A1 EP 2024053112 W EP2024053112 W EP 2024053112W WO 2025168209 A1 WO2025168209 A1 WO 2025168209A1
Authority
WO
WIPO (PCT)
Prior art keywords
rna
endoribonuclease
sample
composition
type iii
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/EP2024/053112
Other languages
English (en)
Inventor
Bernd KETELSEN STRIBERNY
Ulli ROTHWEILER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Arcticzymes ASA
Original Assignee
Arcticzymes ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arcticzymes ASA filed Critical Arcticzymes ASA
Priority to PCT/EP2024/053112 priority Critical patent/WO2025168209A1/fr
Priority to PCT/EP2025/053315 priority patent/WO2025168812A1/fr
Publication of WO2025168209A1 publication Critical patent/WO2025168209A1/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]

Definitions

  • TITLE Compositions comprising a sequence specific endoribonuclease and methods of use
  • Endoribonucleases are a group of enzymes that cleaves internal phosphodiester bonds between adjacent nucleotides of RNA in either single-stranded RNAs or double-stranded RNAs depending on the enzyme.
  • the endoribonuclease may be sequence specific (e.g. restriction endoribonucleases) or sequence independent.
  • RNA molecules longer than 5-10 ribonucleotides are problematic because capping results in only a small shift in molecular weight of approximately 600 Da, which equals roughly to one ribonucleotide. Such small shift in molecular weight prevents a direct down-stream gel -based or mass spectrometry (MS) analysis of long mRNA molecules due to poor resolution.
  • MS mass spectrometry
  • RNA samples and in particular samples comprising long RNA molecules need to be cleaved into shorter fragments before further analysis.
  • RNase H which cleaves an RNA/DNA hybrid is dependent on specific DNA- hybridization
  • AU2016297778, and RNase H-based methods have problems with unspecific and incomplete cleavage of target RNA even if the DNA probe is correctly hybridized.
  • RNase H-based methods requires optimalisation of conditions for each hybridized RNA-DNA oligonucleotide pair in order to achieve complete and specific digestion of the RNA.
  • the Csy4 endoribonuclease is dependent on a guide RNA for recognition and cleavage of its RNA target sequence.
  • ribozymes have been described to be applicable for sequence-specific cleavage of mRNA as well, Vlatkovic et al., Ribozyme assays for quantifying the capping efficiency of in vitro transcribed mRNA, Pharmaceutics, 2022, vol.14, no.2, p.328, and W02015101416.
  • Ribozymes rely of synthesis of ribonucleic acids and need to be used in 1- 10-fold excess over the concentration of the substrate to be analysed. Ribozymes are catalytic RNA molecules and are thus more expensive to produce and also more challenging to work with due to lack of stability.
  • DNAzymes are DNA oligonucleotides with catalytic activity, similar to ribozymes.
  • the most abundant class of deoxyribozymes are ribonucleases which catalyse cleavage of a ribonucleotide phosphodiester bond, Hengesbach, M. et al. Use of DNAzymes for site-specific analysis of ribonucleotide modification, RNA, 2008, vol.14, no. l, p.180-187.
  • endoribonucleases Despite the existence of endoribonucleases there is a continued need for providing further endoribonucleases which permit efficient and simplified methods for RNA analysis or RNA synthesis that overcome one or more of the disadvantages of the endoribonucleases and the methods of prior art.
  • the Type III toxin-antitoxin systems comprises at least three sub families of enzymes, the ToxIN, CptIN and TenpIN, cf. Blower, T.R. et al., “identification and classification of bacterial Type III toxin-antitoxin systems encoding in chromosomal and plasmid genomes”, Nucleic acid research, 2012, Vol. 40, No. 13, p. 6158-6173.
  • sequence specific endoribonucleases of the CptIN subfamily and TenpIN subfamily of the Type III toxin-antitoxin systems cleaves single stranded RNA specifically at its recognition site in the presence of particular concentrations of a monovalent salt, i.e. unspecific catalytic activity (also called star-activity”) of the enzyme is reduced in the absence or at low to moderate concentrations of monovalent salt similarly as shown for endoribonucleases of the ToxIN family.
  • a monovalent salt i.e. unspecific catalytic activity (also called star-activity”) of the enzyme is reduced in the absence or at low to moderate concentrations of monovalent salt similarly as shown for endoribonucleases of the ToxIN family.
  • the CptN- and TenpN endoribonucleases of the CptIN- and TenpIN families are inhibited by certain concentrations of divalent metal cations, which is in contrast to other endoribonucleases, i.e. the enzyme tolerate certain low concentrations of a divalent metal cation, but its enzyme activity is inhibited at higher concentrations.
  • Divalent metal cations are known to stabilise RNA and protein three dimensional structures.
  • cleavage of RNA in the absence or at low concentrations of divalent metal cations may be more complete as such reaction conditions destabilizes the RNA three dimensional structures thereby improving the ToxN endoribonucleases’ accessibility to its target site in the RNA molecule thereby decreasing the amount of enzyme needed for a complete digestion.
  • the CptN- and TenpN endoribonucleases have the advantages that they digest single stranded RNA at specific sites without the need of a hybridized DNA probe or an RNA guide oligo.
  • the families of CptN- and TenpN endoribonucleases are also more efficient and more stable compared to catalytic nucleic acids such as ribozymes or DNAzymes which requires 1-10-fold excess over the concentration of the RNA substrate.
  • a composition comprising an isolated endoribonuclease of the Type III toxin-antitoxin systems, wherein a concentration of a monovalent salt in the composition is ⁇ 150 mM, such as about ⁇ 100 mM and wherein the monovalent salt is preferably an alkali metal salt and wherein the endoribonuclease is selected from CptN endoribonucleases or TenpN endoribonucleases.
  • the composition comprises a concentration of an alkali metal salt about ⁇ 75 mM, such as about ⁇ 55 mM, such as from about 20 mM to about 75 mM, such as from about 20 mM to about 55 mM.
  • the composition is a solution for application to a sample comprising at least one polyribonucleic acid (RNA) molecule.
  • RNA polyribonucleic acid
  • said sample has a volume from about > 0.1 pl.
  • said sample has a volume from 0.1 pl about to about 500pl, preferably from about 0.1 pl to about 300 pl, preferably from about 0.1 pl to about 250 pl, preferably from about 0.1 pl to about 200 pl, more preferably from about 0.1 pl to about 150 pl, more preferably from about 0.1 pl to about 100 pl, more preferably from about 0.1 pl to about 75 pl, more preferably from about 0.1 pl to about 50 pl.
  • the monovalent salt of the composition or sample is an inorganic salt comprising alkali metal ions.
  • the monovalent salt is preferably an alkali metal salt.
  • the alkali metal ions of the salt are selected from Na+, K+, Li+, Rb+, Cs+ and Fr+ or any combinations thereof.
  • anions of the salts comprising alkali metals ions are preferably selected from fluorine (F), chlorine (Cl), bromine (Br), iodine (I), sulphates, phosphates or hydroxides or any suitable combinations thereof.
  • the alkali metal salt is selected from NaCl, KC1, Na2SO4, K2SO4, KOH, NaOH, Na-Phosphates, K-Phopshates or any suitable combinations.
  • composition or sample is essentially without divalent metal cations.
  • the divalent metal cations are preferably Mg 2+ or Mn 2+ .
  • the composition or sample is essentially without divalent metal cations, i.e. a concentration of divalent metal cations in the composition is about ⁇ 3mM, preferably about ⁇ 2mM, more preferably about ⁇ ImM.
  • the composition or sample is essentially without divalent metal cations, i.e. comprises ratio of concentration of a divalent metal cation to the concentration of divalent ion chelating agent in the composition providing that the concentration of free divalent metal cation present in the composition is about ⁇ 3 mM, preferably about ⁇ 2mM, more preferably about ⁇ ImM.
  • the composition or sample comprises a concentration of a divalent ion chelating agent of about ⁇ lOmM.
  • the divalent ion chelator is preferably EDTA or EGTA.
  • the isolated CptN endoribonuclease or an enzymatically active fragment thereof comprises amino acid sequence of SEQ ID No.l or comprising an amino acid sequence which is at least 30% identical to SEQ ID No. l.
  • the isolated CptN endoribonuclease or an enzymatically active fragment thereof comprises amino acid sequence of SEQ ID No.l or comprising an amino acid sequence which is at least 70% identical to SEQ ID No. l.
  • the isolated CptN endoribonuclease or an enzymatically active fragment thereof comprises an amino acid sequence of SEQ ID No. l or comprises an amino acid sequence which is at least 75%, 80%, 85%, 90%, 92%, 94%, 95%, 98% or 99% identical to SEQ ID No. l.
  • the isolated TenpN endoribonuclease or an enzymatically active fragment thereof comprises amino acid sequence of SEQ ID No.2 or comprising an amino acid sequence which is at least 30% identical to SEQ ID No.2.
  • the isolated TenpN endoribonuclease or an enzymatically active fragment thereof comprises amino acid sequence of SEQ ID No.2 or comprising an amino acid sequence which is at least 70% identical to SEQ ID No.2.
  • the isolated TenpN endoribonuclease or an enzymatically active fragment thereof comprises an amino acid sequence of SEQ ID No. l or comprises an amino acid sequence which is at least 75%, 80%, 85%, 90%, 92%, 94%, 95%, 98% or 99% identical to SEQ ID No.2.
  • the isolated CptN endoribonucleases disclosed herein is not in a complex with ToxI RNA.
  • the isolated TenpN endoribonucleases disclosed herein is not in a complex with ToxI RNA.
  • composition or a sample comprises a ToxN endoribonuclease or an enzymatically active fragment thereof, said CptN endoribonuclease comprises amino acid sequence of SEQ ID No. l or comprising an amino acid sequence which is at least 30% identical such as 70% identical to SEQ ID No.1 wherein
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM.
  • composition or sample comprises a CptN endoribonuclease or an enzymatically active fragment thereof, said CptN endoribonuclease comprises amino acid sequence of SEQ ID No. l or comprising an amino acid sequence which is at least 30% identical such as at least 70% identical to SEQ ID No.1 wherein
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM; and wherein
  • composition or sample is essentially without free divalent metal cations wherein the divalent metal cations are preferably Mg2+ or Mn2+ and wherein the divalent metal cations are provided as inorganic salts, such as MgC12 or MnC12.
  • composition or sample comprises a CptN endoribonuclease or an enzymatically active fragment thereof, said CptN endoribonuclease comprises amino acid sequence of SEQ ID No. l or comprising an amino acid sequence which is at least 30% identical such as at least 70% identical to SEQ ID No.1 wherein
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM; and wherein
  • the divalent metal cations are preferably Mg 2+ or Mn 2+ and wherein the divalent metal cations are provided as inorganic salts such as MgCh or MnCh.
  • the divalent metal cations are preferably Mg 2+ or Mn 2+ and provided as inorganic salts such as MgCh or MnCh and
  • the divalent ion chelating agent is preferably EDTA or EGTA.
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM.
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM; and wherein
  • composition or sample is essentially without free divalent metal cations wherein the divalent metal cations are preferably Mg2+ or Mn2+ and wherein the divalent metal cations are provided as inorganic salts, such as MgC12 or MnC12.
  • composition or sample comprises a TenpN endoribonuclease or an enzymatically active fragment thereof, said TenpN endoribonuclease comprises amino acid sequence of SEQ ID No.2 or comprising an amino acid sequence which is at least 30% identical such as at least 70% identical to SEQ ID No.2 wherein
  • composition or sample comprises a ToxN endoribonuclease or an enzymatically active fragment thereof
  • said TenpN endoribonuclease comprises amino acid sequence of SEQ ID No.2 or comprising an amino acid sequence which is at least 30% identical, such as at least 70% identical to SEQ ID No.2 wherein
  • -concentration of monovalent salt in the composition or sample preferably about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, more preferably from about 20 mM to about 75 mM, more preferably from about 20 mM to about 55 mM; and wherein
  • a method of cleaving single stranded RNA molecules in a sample comprising the steps: a. providing a sample comprising at least one single stranded RNA molecule comprising a cleavage site for an isolated endoribonuclease of the Type III toxin-antitoxin systems; and b.
  • said single stranded RNA molecule in step a) is a concatemer comprising multiple copies of precursors of either mRNA, siRNA, circular RNA precursors, microRNA or ribozyme and wherein the concatemeric RNA molecule comprising a cleavage site for an endoribonuclease of the Type III toxin-antitoxin systems between each copy of precursors of mRNA, siRNA, circular RNA, microRNA or ribozyme.
  • the cleavage step will typically be incubation which permits cleavage of at least a portion said RNA molecule present in the sample.
  • the at least one single stranded RNA molecule comprising a cleavage site for an isolated TenpN endoribonuclease.
  • the incubation takes place at around 10°C to around 50°C, such as around 10°C to 30°C, preferably around 15°C.
  • a method for preparing single stranded circular RNA molecules comprising the steps: a. providing a sample comprising at least one single stranded RNA molecule wherein the RNA molecule comprises a cleavage site for an isolated endoribonuclease of the Type III toxin-antitoxin systems; b.
  • the sample comprising an endoribonuclease of the Type III toxin-antitoxin systems is the sample as described in the first aspect and embodiments thereof.
  • the at least one single stranded RNA molecule comprising a cleavage site for an isolated CptN endoribonuclease.
  • the at least one single stranded RNA molecule comprising a cleavage site for an isolated TenpN endoribonuclease.
  • a method of synthesizing siRNAs comprising the steps: a. providing a sample comprising at least one rolling circle transcribed concatemeric RNA molecule comprising cleavage sites for two different endoribonuclease of the Type III toxin-antitoxin systems, for example a CptN -A and CptN -B, having different recognition sites, wherein the recognition sites for CptN -B is situated between tandem repeats and recognition sequences for CptN -A is situated within the tandem repeats; b.
  • a standard single-strand specific ribonuclease such as RNase T1 thereby producing double strand
  • the endoribonuclease of the Type III toxin-antitoxin systems is a TenpN endoribonuclease.
  • the composition and sample comprising isolated endoribonuclease of the Type III toxin-antitoxin systems is the composition and sample as described in the first aspect and embodiments thereof.
  • a fourth aspect there is provided method for determining 5 ’-capping efficiency of a RNA molecule wherein the method comprises the steps: a. providing a sample comprising at least one single stranded mRNA molecule comprising a cleavage site for an endoribonuclease of the Type III toxin-antitoxin systems in the 5’UTR of said mRNA; b.
  • the 5’ terminal RNA fragment has a length from about 2 ribonucleotides to about 100 ribonucleotides, preferably 5 to 50, more preferably 5 to 10.
  • composition and sample comprising endoribonuclease of the Type III toxin-antitoxin systems is the composition and sample as described in the first aspect and embodiments thereof.
  • composition and sample comprising CptN endoribonucleases.
  • composition and sample comprising TenpN endoribonucleases.
  • a fifth aspect there is provided method for determining Poly(A) tail length distribution of a RNA molecule wherein the method comprises the steps: a. providing a sample comprising at least one single stranded mRNA molecule comprising a cleavage site for a endoribonuclease of the Type III toxin-antitoxin systems upstream of the Poly(A) tail of said mRNA; b.
  • composition and sample comprising endoribonuclease of the Type III toxin-antitoxin systems is the composition and sample as described in the first aspect and embodiments thereof.
  • composition and sample comprising CptN endoribonucleases.
  • RNA fingerprinting comprises the steps: a. providing a sample comprising a at least one single stranded RNA molecule with unknown sequence; b. contacting said sample from step a) with a endoribonuclease of the Type III toxin-antitoxin systems under conditions that permit cleavage of at least a portion of said RNA molecules thereby obtaining a plurality of RNA fragments, wherein concentration of a monovalent salt in the sample is about ⁇ 150 mM, such as about ⁇ 100 mM and wherein the monovalent salt is preferably an alkali metal salt; and c. separation and detection of the fragmented RNA molecule from step b, thereby obtaining a fingerprint of said RNA molecule with unknown sequence and compare the obtained fingerprint with fingerprints from RNA molecules with known sequence.
  • composition and sample comprising endoribonuclease of the Type III toxin-antitoxin systems is the composition and sample as described in the first aspect and embodiments thereof.
  • composition and sample comprising CptN endoribonucleases. In one embodiment of the sixth aspect the composition and sample comprising TenpN endoribonucleases.
  • the separation and detection step is selected from gel electrophoresis, capillary gel-electrophoresis (CGE), PAGE, high pressure liquid chromatography (HPLC), mass spectrometry (MS) or LC-MS, IP RP HPLC and LC-UV.
  • CGE capillary gel-electrophoresis
  • HPLC high pressure liquid chromatography
  • MS mass spectrometry
  • LC-MS IP RP HPLC and LC-UV.
  • composition and sample comprising endoribonuclease of the Type III toxin-antitoxin systems is the composition and sample as described in the first aspect and embodiments thereof.
  • kit comprising: a. The composition according to the first aspect and embodiments therein; and b. A second composition comprising a second enzyme selecting from a group consisting of an RNA polymerase, RNA ligase for ligating single stranded RNA molecules, a pyrophosphatase, a phosphatase, a kinase or any other nucleic acid or ribonucleic acid modifying enzymes and at least one further endoribonuclease of the Type III toxin-antitoxin systems with a different recognition site from the endoribonuclease of the Type III toxin-antitoxin systems of a).
  • a second enzyme selecting from a group consisting of an RNA polymerase, RNA ligase for ligating single stranded RNA molecules, a pyrophosphatase, a phosphatase, a kinase or any other nucleic acid or ribonucleic acid modifying enzymes
  • FIG. 3 Profiling ToxN(ET-Nl) endoribonuclease activity: (1) 50 mM Tris-HCl pH 7.0, (2) 50 mM Tris-HCl pH 7.5, (3) 50 mM Tris-HCl pH 8.0, (4) 50 mM Tris- HCl pH 9.0; (A) MW DNA ladder; (B) control without ToxN; (C) 0 mM NaCl; (D) 25 mM NaCl; (E) 50 mM NaCl, (F)75 mM NaCl; (G) 100 mM NaCl; (H)125 mM NaCl; (I) 150 mM NaCl, (J) 175 mM NaCl.
  • FIG. 4a Profiling ToxN(ET-Nl) endoribonuclease activity: (A): MW DNA ladder, (B): w/o ToxN, (C): OmM MgCh, (D): ImM MgCh; (E): 2mM MgCh, (F): 3mM MgCh, (G): 4mM MgCh, (H): 5mM MgCh, (I): 6mM MgCh, (J): 7mM MgCh
  • Figure 4b Profiling ToxN(ET-Nl) endoribonuclease activity: Lanes 1 to 6: lOmM MgCL, 5mM MgCL, 3mM MgCL, ImM MgCL, OmM MgCL, No enzyme added; Lanes 7 to 12: lOmM MnCh, 5mM MnCh, 3mM MnCh, ImM MnCh, OmM MnCh, No enzyme added.
  • FIG. 6 Profiling ToxN (ET-N1) endoribonuclease activity: (A): MW DNA ladder, (B): w/o ToxN, (C): 5 min., (D): 10 min.; (E): 15 min., (F): 20 min., (G): 30 min., (H): 40 min., (I): 50 min., (J): 60 min.
  • FIG. 8 Profiling ToxN (ET-N1) endoribonuclease activity: (A): MW DNA ladder, (B): w/o ToxN, (C): 25 °C, (D): 25.2 °C; (E): 26 °C, (F): 27 °C, (G): 29 °C, (H): 31 °C, (I): 33 °C, (J): 33.6 °C, (K): 34 °C, (L): 35 °C, (M): 35.7 °C, (N): 36 °C.
  • Figure 9a illustrating the concept of determining 5 ’-capping efficiency of mRNA transcripts using a ToxN endoribonuclease.
  • Figure 9b depicts a capping analysis of an IVT (In Vitro Translated) construct of 40 bases made with the commercial kit “CleanCap”.
  • the dark grey triangles show the 13 base (uncapped) and 14 base (capped) fragments after cleavage reaction with E.coli ToxNl.
  • the addition bands marked with white triangles are caused by RNA initiation slippage.
  • Lane 1 DNA Ladder: bands 50, 20, 15, 8, 6 bases; Lane 2: Capped IVT cut with E.coli ToxNl; Lane 3: uncapped IVT cut with E.coli ToxNl; Lane 4: capped IVT uncut; Lane 5: uncapped IVT uncut.
  • the plasmid was linearized with Hindlll.
  • the 40 base nucleotide mRNA has the ToxNl (ET-N1) cleavage site after 10 bases from the 5 ’end resulting in two fragments of 13 and 27 bases respectively. Successful capping can be seen by a band shift of the band to higher molecular weight.
  • Figure 9c depicts a capping analysis of an IVT (In Vitro Translated) construct.
  • the gel picture in the middle is an excerpt of the gel picture to the left.
  • the diagrams to the right is a quantification of capped ( «, pl) and uncapped (p2) mRNA fragments.
  • Figure 9d depicts a capping analysis of an IVT (In Vitro Translated) construct.
  • Lane 1 ET-N1 enzyme and an uncapped RNA oligo (GEM3Zf);
  • Lane 2 ET-N1 enzyme and capped RNA oligo (GEM3Zf);
  • lane 3 uncapped RNA oligo (GEM3Zf) w/o enzyme;
  • lane 4 capped RNA oligo (GEM3Zf) w/o enzyme.
  • Figure 10a illustrating the concept of mRNA-fingerprinting of an unknown virus strain in a sample.
  • SI, S2, S3 RNA samples isolated from three different RNA viruses with unique distribution of recognition sites for ToxN.
  • V RNA sample isolated from unknown RNA virus. Analysis of fragment distribution by electrophoresis illustrates that the unknown virus (V) is a type (S2) virus.
  • Figure 10c depicts the ratio of the substrates in a mixture based on analysis of the band intensities of the FAM labelled oligonucleotides in figure 10b.
  • Figure 12 illustrates rolling circle transcribed concatemeric RNA sequences to produce siRNAs.
  • the transcribed sequence comprising ToxN recognition sequences for two different ToxN enzymes, ToxN-A and ToxN-B.
  • the ToxN-B endoribonuclease will digest the RNA between pairs of concatemeric RNA sequences.
  • Concatemeric RNA hybridize to form a hairpin structure.
  • the ToxN-A enzyme cleaves RNA at its recognition site in the hairpin loop, the 5 ’-end and 3 ’end of the concatemeric RNA are digested with a single-strand specific RNase to remove the rest of the ToxN recognition sequences thereby producing a siRNA.
  • Figure 14 profiling EcoToxNl (ET-N1), EcoToxN5 (ET-N5) and BtuToxN (BT- Nl) endoribonuclease activity.
  • Lane 1 RNA oligo ladder;
  • lane 2 ET-N1 and QI RNA oligo comprising ET-N1 recognition site;
  • lane 3 QI RNA oligo w/o enzyme;
  • lane 4 ET-N5 and RS2 RNA oligo comprising ET-N5 recognition site;
  • lane 5 RS2 RNA oligo w/o enzyme;
  • lane 6 ET-N5 and RS3 RNA oligo comprising ET-N5 recognition site;
  • lane 7 RS3 RNA oligo w/o enzyme;
  • lane 8 UTR-sequence with no recognition site for ET-N5;
  • lane 9 UTR-sequence w/o enzyme;
  • lane 10 RS3 RNA oligo with recognition site for BT
  • a polyribonucleotide refers to a polymeric form of ribonucleotides.
  • a polyribonucleotide consists of ribonucleotides only.
  • a polyribonucleotide comprises ribonucleotides, and one or more modified ribonucleotides, but does not include any deoxyribonucleotides.
  • a polyribonucleotide comprises ribonucleotides, and may comprise one or more modified ribonucleotides, and one or more deoxyribonucleotides (including modified deoxyribonucleotides).
  • ribonucleic acid RNA
  • polyribonucleotide are used interchangeably and refer to a polymeric form of ribonucleotides of any length.
  • An endoribonuclease cleaves either a single- or double- stranded RNA.
  • the endoribonucleases described in this patent application cleaves single- stranded RNA.
  • RNA digestion or “RNA cleavage” are used interchangeably and refers to hydrolysis of phosphodiester bonds within a polyribonucleotide backbone in a sample.
  • Endoribonucleases may cleave sequences which are similar to their target recognition sequence. This non-specific activity has been termed “star-activity” and should preferably be avoided. Star activity results from the recognition and cleavage of secondary cleavage sites in addition to a primary cleavage site. The secondary cleavage sites differ by one or more ribonucleotides from the primary recognition site. The star activity is characterised by the appearance of further bands in a gel electrophoresis which appear in addition to the band pattern of the complete digestion arising by specific cleavage.
  • the present invention also covers the exact terms, features, values and ranges etc. in case these terms, features, values and ranges etc. are used in conjunction with terms such as about, around, generally, substantially, essentially, at least etc. (i.e. , "about 3" shall also cover exactly 3 or "essentially free” shall also cover “free of/ without”).
  • ToxN is a family of endoribonucleases from subfamily ToxIN of the Type III toxinantitoxin (TA) systems.
  • the toxin (ToxN) is a protein/enzyme, while the antitoxin (ToxI) consists of multiple repeats of RNA.
  • the toxic effects of the protein are neutralized by the specific antitoxin RNA sequence (ToxI).
  • the toxin assembles with the individual antitoxin repeats into a cyclic complex in which the antitoxin forms a pseudoknot structure.
  • RNA antitoxin binds tightly to the toxin to form a hetero tetrameric or hetero hexameric cyclic, unique self-closing RNA-protein complexes, in which the toxin and antitoxin are arranged alternately in a 1 : 1 ratio, ToxIN complex.
  • Identification and functional characterization of the structure of the ToxN-an titoxin (RNA) complex from E.coli is described in Manikandan, P. et al., Identification, functional characterization, assembly and structure of ToxIN type III toxin-antitoxin complex from E.coli, Nucleic acid research, 2022, vol.50, no.3, p.1687-1700.
  • CptN endoribonuclease
  • ToxI antagonist RNA molecule/inhibitor of CptN
  • CptIN heteromeric protein/RNA complex of CptN with ToxI
  • TenpN endoribonuclease
  • ToxI antagonist RNA molecule/inhibitor of TenpN
  • TeenpIN heteromeric protein/RNA complex of TenpN with ToxI
  • the number of ribonucleotides in the recognition sequence for the endoribonucleases of the Type III toxin-antitoxin systems may vary.
  • the recognition sequence may be from 2 to 20 ribonucleotides.
  • Preferably the recognition sequence is from 3 to 15 ribonucleotides, more preferably 4 to 10 ribonucleotides, 4 to 9 ribonucleotides or 4 to 6 ribonucleotides.
  • the Type III toxin-antitoxin systems comprises at least three sub families of enzymes, the ToxN subfamily, the CptIN subfamily and the TenpIN subfamily, cf. Blower, T.R.
  • a sequence specific endoribonuclease of the Type III toxin-antitoxin systems cleaves single stranded RNA specifically at its recognition site in the presence of particular concentrations of a monovalent salt i.e. unspecific catalytic activity (also called star-activity”) of the enzyme is reduced or absent at particular concentrations of a monovalent salt.
  • a monovalent salt i.e. unspecific catalytic activity (also called star-activity”) of the enzyme is reduced or absent at particular concentrations of a monovalent salt.
  • the unspecific catalytic i.e. its star-activity of endoribonuclease of the Type III toxinantitoxin systems is reduced or absent at low concentrations or without divalent metal cations, preferably Mg 2+ or Mn 2+ , present in the composition or sample.
  • Free divalent cation is to be understood as not bound to a divalent ion chelator such as EDTA or EGTA.
  • the endoribonuclease of the Type III toxin-antitoxin systems catalytic activity is also inhibited by concentrations of divalent cations above a certain concentration.
  • the divalent metal cations such as Mg2+ or Mn2+ present in the composition or sample may be bound to RNA thereby inhibiting the ToxN access to its target site.
  • the inventors have also shown that, surprisingly, it is not necessary to remove divalent metal cations from a composition or sample comprising a endoribonuclease of the Type III toxin-antitoxin systems endoribonuclease, rather the sequence specific catalytic activity may be maintained by a divalent cation chelator such as EDTA or EGTA.
  • a divalent cation chelator such as EDTA or EGTA.
  • essentially free of divalent metal cations in the context of a divalent ion chelating agent is meant that the ratio of the concentration of a divalent cation, preferably Mg2+ or Mn2+ to the concentration of divalent ion chelating agent, e.g. EDTA or EGTA, in the sample is from 3 : 1 to 1 : 10, such as (e.g. Mg 2+ or Mn 2+ : EDTA or EGTA).
  • the ToxN enzyme tolerates a low concentration of a divalent metal cation present in the sample that is not bound to a divalent ion chelator without losing its catalytic activity.
  • a further advantage is that EDTA or EGTA present in the sample may not need to be removed as the catalytic activity and specificity of the ToxN enzyme is not significantly affected by the presence of a divalent ion chelator, e.g. EDTA or EGTA.
  • a divalent ion chelator e.g. EDTA or EGTA.
  • composition comprising isolated endoribonuclease of the Type III toxinantitoxin systems is not comprised in a complex with a Toxl.
  • composition or sample comprising an isolated endoribonuclease of the Type III toxin-antitoxin systems or an enzymatically active fragment of the endoribonuclease of the Type III toxin-antitoxin systems may not comprise monovalent salts.
  • composition or sample comprising an isolated endoribonuclease of the Type III toxin-antitoxin systems or an enzymatically active fragment of the ToxN may not comprise free divalent metal cations.
  • an enzymatically active fragment thereof’ of the endoribonuclease of the Type III toxin-antitoxin systems is to be understood to mean an endoribonuclease wherein the catalytic activity of the endoribonuclease is maintained in the truncated form.
  • Example 3 provide a suitable assay to measure endoribonuclease activity.
  • the CptN endoribonucleases may be the CptN with an amino acid sequence of SEQ ID NO: 1 (NCBI Acc. No.: PDB: 7D8O A) or an amino acid sequence which is at least about 70% identical to SEQ ID NO: 1.
  • SEQ ID NO: 1 NCBI Acc. No.: PDB: 7D8O A
  • the CptN endoribonuclease may be a CptN endoribonuclease or an enzymatically active fragment thereof wherein the CptN comprises an amino acid sequence which is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 98% or 99% identical to SEQ ID No. l.
  • the TenpN endoribonucleases may be the TenpN with an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence which is at least about 70% identical to SEQ ID NO: 2.
  • Example of sequences with least 70% sequence identity to SEQ ID NO: 2 is the TenpN with an amino acid sequence of SEQ ID NO: 2 or an amino acid sequence which is at least about 70% identical to SEQ ID NO: 2.
  • the TenpN endoribonuclease may be a TenpN endoribonuclease or an enzymatically active fragment thereof wherein the TenpN comprises an amino acid sequence which is at least 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 92%, 94%, 95%, 98% or 99% identical to SEQ ID No.2.
  • sequence identity may be at least 29%, 29.5% or 29.9% to SEQ ID No. l or SEQ ID No.2.
  • sequence identity may be at least 69%, 69.5% or 69.9% to SEQ ID No. l or SEQ ID No.2.
  • the CptN endoribonuclease may consists of the amino acid sequence of SEQ ID No 1. Enzymatically active fragments thereof are also provided. An CptN or TenpN endoribonuclease having an amino acid sequence which is at least 30% identical to SEQ ID No. l or SEQ ID No.2 may be obtained from a prokaryotic organism.
  • An CptN or TenpN endoribonuclease having an amino acid sequence which is at least 70% identical to SEQ ID No. l or SEQ ID No.2 may be obtained from a prokaryotic organism.
  • sequence identity when referring to “sequence identity” of proteins, an amino acid sequence having at least x% identity to a second amino acid sequence means that x% represents the number of amino acid residues in the first sequence which are identical to their matched amino acid residues of the second sequence when both sequences are optimally aligned via a global alignment, relative to the total length of the second amino acid sequence. Both sequences are optimally aligned when x is maximum by using Clustal Omega with default settings, the multiple protein sequence alignment tool from EMBL-EBI.
  • the composition is a solution, preferably an aqueous solution.
  • solution as used herein means a liquid mixture in which one or more minor components (solutes) are uniformly distributed within a major component (solvent).
  • minor component (solute) of a solution is soluble in the major component (solvent).
  • the major component i.e. solvent, i.e. liquid phase
  • the solution comprises water.
  • the solutions of the present invention comprise at least an isolated endoribonuclease of the Type III toxin-antitoxin systemsor an enzymatically active fragment thereof as a minor component.
  • the solution is a reagent for application to a sample comprising one or more RNA molecules.
  • a reagent is applied to a sample in order for the endoribonuclease of the Type III toxin-antitoxin systems in said reagent to digest said one or more ribonucleotides present in the sample.
  • the sample comprises multiple ribonucleotides.
  • the solution comprises an endoribonuclease of the Type III toxin-antitoxin systems or enzymatically active fragment thereof.
  • sample refers to a composition comprising single stranded RNA molecules.
  • composition also comprises a buffer.
  • Suitable buffers are well known in the art and any such buffer may be used. It would be within the competencies of a skilled person in the art to identify a suitable buffer.
  • the buffer has a buffering range of about pH 5.5 to about pH 9, preferably about pH 6.5 to about pH 9, preferably about pH 7 to about pH 9, more preferably about pH 7 to about pH 8.5.
  • the buffer may be Tris, HEPES or phosphate buffer.
  • the buffer is present in the composition or sample at a concentration of ImM to 200 mM, preferably 10 mM to 200 mM, preferably 20 mM to 150 mM, more preferably 25 mM to 100 mM.
  • Tris-HCI is present at a concentration of 25 mM to 150 mM, more preferably 40 mM to 100 mM, more preferably about 50 mM.
  • the samples may have a volume of > 0.1 pl.
  • the samples of the invention have a volume of from about 0.1 pl to about 500 pl, such as from about 0.1 pl to about 300 pl, such as from about 0.1 pl to about 250 pl, such as from about 0.1 pl to about 200 pl, such as from about 0.1 pl to about 150 pl, such as from about 0.1 pl to about 100 pl, such as from about 0.1 pl to about 75 pl, such as from about 0.1 pl to about 50 pl.
  • the skilled person is able to determine the appropriate concentration of the enzyme to include in the sample and the reaction mixture in order to obtain digestion of preferably all RNA molecules in the sample and at the same time avoiding unspecific digestion and star activity.
  • the reaction mixture may comprise further components that may be present due to having been added at an earlier stage of the workflow and tolerable in the reaction assay, e.g. DTT, nucleotides, S-adenosylmethionine (SAM) or other enzymes.
  • DTT is a reducing agent that stabilizes disulphide bonds within enzymes and thereby stabilizing the enzyme structure.
  • composition or sample comprising CptN or TenpN endoribonuclease or an enzymatically active fragment thereof comprises preferably a specific concentration of a monovalent salt.
  • the monovalent salt present in the composition or sample may selected from inorganic salts comprising alkali metal ions wherein the alkali metal ions are selected from Na+, K+, Li+, Rb+, Cs+ and Fr+ or any combinations thereof.
  • the monovalent salt is an alkali metal salt.
  • the alkali metal ions of the salt are selected from Na+, K+, Li+ and Rb+.
  • the anions of the salts comprising alkali metals ions are preferably selected from fluorine (F), chlorine (Cl), bromine (Br), iodine (I), sulphates, phosphates or hydroxides or any suitable combinations thereof.
  • alkali metal salts are NaCl, KC1, Na2SO4, K2SO4, KOH, NaOH, Na- Phosphates, K-Phopshates or any suitable combinations.
  • composition or samples comprising a particular concentration of a monovalent salt is referred herein to a composition or sample that comprises a concentration of monovalent salt ⁇ 150 mM.
  • composition or sample may not comprise a monovalent salt.
  • the composition or sample comprising an endoribonuclease of the Type III toxin-antitoxin systems or an enzymatic active fragment thereof comprises a concentration of alkali metal salt in the composition or sample ⁇ 150 mM, about ⁇ 100 mM, about ⁇ 75 mM, about ⁇ 55 mM, from about 20 mM to about 75 mM, from about 20 mM to about 55 mM.
  • compositions or samples comprising an endoribonuclease of the Type III toxin-antitoxin systems or an enzymatic active fragment thereof are essentially without free divalent metal cations, i.e. the composition or sample may comprise low concentration of a divalent metal cation. Free divalent metal cations are referred herein to divalent metal cations not bound to a divalent cation chelator such as EDTA or EGTA.
  • compositions or samples may comprise a concentration of free divalent metal cation about ⁇ 3 mM.
  • composition or samples may be without free divalent metal cations.
  • the free divalent cations are preferably selected from Mg 2+ and Mn 2+ .
  • composition or samples may be without free Mg 2+ .
  • composition or samples may be without free Mn 2+ .
  • the concentration of free Mg 2+ and/or free Mn 2+ in the compositions and samples are about ⁇ 2 mM, more preferably about ⁇ 1 mM.
  • composition or sample comprising an endoribonuclease of the Type III toxinantitoxin systems or an enzymatic active fragment thereof may comprise a concentration of free Mg 2+ and/or Mn 2+ in the composition or sample in the range from 0 to about 1 mM, from about 1 pM to about 1 mM, from about 1 pM to about 0.9 mM, from about 1 pM to about 0.8 mM, from about 1 pM to about 0.7 mM, from about 1 pM to about 0.6 mM, from about 1 pM to about 0.5 mM.
  • composition or sample comprising an endoribonuclease of the Type III toxinantitoxin systems or an enzymatic active fragment thereof may comprise a ratio of concentration of a divalent metal cation to a concentration of a divalent ion chelating agent in the composition or sample such that the max concentration of free divalent cation in the composition or sample, i.e . not bound to a divalent ion chelator is not above 3 mM, preferably not above 2 mM and more preferably not above 1 mM.
  • composition or sample comprising an endoribonuclease of the Type III toxinantitoxin systems or an enzymatic active fragment thereof may comprise a concentration of free Mg 2+ in the composition or sample in the range from 0 to about 3 mM.
  • composition or sample comprising an endoribonuclease of the Type III toxinantitoxin systems or an enzymatic active fragment thereof may comprise a concentration of free Mn 2+ in the composition or sample in the range from 0 to about 1 mM.
  • composition or sample comprising an endoribonuclease of the Type III toxinantitoxin systems or an enzymatic active fragment thereof may comprise a concentration of a divalent ion chelator of about ⁇ 10 mM.
  • the divalent ion chelator is preferably EDTA or EGTA.
  • compositions and samples comprising divalent metal cations are preferably added as a divalent salt.
  • a divalent salt is a salt in which at least one of the counter ions is divalent, e.g. MgCh or MnCh.
  • the salts are preferably inorganic.
  • An inorganic salt is a salt in which neither of the counter ions comprises carbon.
  • the mono- or divalent salts are preferably inorganic salts.
  • compositions and samples comprise monovalent salts and preferably also monovalent anions which are counterions.
  • monovalent salts preferably also monovalent anions which are counterions.
  • concentrations of monovalent salts disclosed herein are, inherently, the preferred concentrations of monovalent counterions, and vice versa.
  • free Mg 2+ or Mn 2+ in the sample is denoted herein as not bound to EDTA or EGTA.
  • the ratio of concentration of a divalent metal cation to the concentration of divalent ion chelating agent in the composition or sample may be for example 2 mM : 1 mM, 5mM : 5mM, 5mM : lOmM, 10 mM : 10 mM or any other alternative ratio combinations providing that the concentration of free divalent metal cation in the composition or sample is about ⁇ 1 mM and the concentration of divalent ion chelator is preferably about ⁇ 10 mM.
  • ToxN endoribonuclease A method of preparing ToxN endoribonuclease is described in Manikandan, P. et al., Identification, functional characterization, assembly and structure of ToxIN type III toxin-antitoxin complex from E.coli, Nucleic acid research, 2022, vol.50, no.3, p.1687-1700 and further described in Example 1.
  • the endoribonuclease and the enzymatically active fragments thereof or nucleic acid molecules encoding the endoribonuclease may be isolated from a natural source such as a bacteria, for example E. coli, Pectobacterium atrosepticum, Bacillus thuringiensis subsp. Kurstaki, Lactococcus lactis subsp. lactis or [Eubacterium] rectale.
  • a bacteria for example E. coli, Pectobacterium atrosepticum, Bacillus thuringiensis subsp. Kurstaki, Lactococcus lactis subsp. lactis or [Eubacterium] rectale.
  • the enzyme may be produced recombinantly in a host cell and isolated and purified therefrom.
  • the host cell is not, or not from an organism which naturally express the gene encoding the ToxN endoribonuclease, i.e. the host cell is a heterologous host cell such as a yeast cell, an insect cell, a human cell line or a bacterial cell, preferably E. coli.
  • Nucleic acid sequences encoding the endoribonuclease of the Type III toxinantitoxin systems endoribonuclease or enzymatic active fragments thereof may be amplified using PCR from genomic DNA, isolated as a cDNA or may be ordered by a commercial supplier such as GENEWIZ, GeneArt from Thermo Fisher Scientific or Genscript.
  • nucleic acid sequence encoding an endoribonuclease of the Type III toxin-antitoxin systems or enzymatic active fragments thereof may be codon optimized for increased protein production in a heterologous host cell.
  • CodonW is an example of an open source software program that may be used.
  • the GeneOptimizer Algorithm Using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization.
  • nucleic acid molecule encoding a ToxN endoribonuclease or encoding an enzymatic active fragment thereof may be inserted in a suitable expression vector comprising necessary transcriptional and translational elements for expression that are appropriate for the chosen host cell.
  • suitable expression vector comprising necessary transcriptional and translational elements for expression that are appropriate for the chosen host cell.
  • Examples of commonly used expression vectors are plasmids or viruses.
  • the expression vector may comprise a strong promoter
  • bacteriophage T5 and T7 are examples of strong promoters for expression in E. coli.
  • the promoter may be regulated by comprising chemical switches.
  • Example of inducible promoters for use in E. coli is the commonly used lac promoter induced by Isoropyl-beta-D-thiogalactoside (IPTG) (Hansen LH, Knudsen S, Sorensen SJ,"The effect of the lacY gene on the induction of IPTG inducible promoters, studied in Escherichia coli and Pseudomonas fluorescens", Curr. Microbiol.
  • a further aspect of the invention is a method of expression of a endoribonuclease of the Type III toxin-antitoxin systems endoribonuclease or an enzymatic active fragment thereof as described above in a suitable heterologous cell.
  • the host cell may be a bacterium or a yeast cell.
  • the expression of the enzyme is in a bacterial host cell, more preferably E.coli, BL21 (DE3) cells.
  • Transformation of the above described expression vector comprising the endoribonuclease of the Type III toxin-antitoxin systems may be performed by methods well known to a skilled person, e.g. by using chemically competent cells.
  • the endoribonuclease of the Type III toxin-antitoxin systems may be synthesized using recombinant DNA technology.
  • the endoribonuclease may be produced using a cell-free expression system or chemical synthesis of a endoribonuclease of the Type III toxin-antitoxin systems.
  • a endoribonuclease of the Type III toxin-antitoxin systems enzyme comprising a signaling peptide for secretion into cell culture media may be isolated and purified from the host cell culture media using any technique known in the art and well described in literature. Examples of such techniques or any combination may include precipitation, ultrafiltration, different chromatographic techniques e.g. sizeexclusion chromatography, immobilized metal affinity column chromatography and/or immunoadsorption chromatography.
  • a endoribonuclease of the Type III toxin-antitoxin systems produced intracellularly may be isolated and purified also using techniques well known to a skilled person. Examples of methods for preparation of cell lysates from E. coli cells are homogenization, sonication or enzymatic lysis using lysozyme. After the endoribonuclease of the Type III toxin-antitoxin systems is released from the lysed cells the enzyme may be subject to any method of purification for example sizeexclusion chromatography, immobilized metal affinity column chromatography and/or immunoadsorption chromatography.
  • the endoribonuclease of the Type III toxin-antitoxin systems may comprise a C- terminal or N-terminal His-tag to ease isolation, purification and/or identification of the enzyme.
  • the purified endoribonuclease of the Type III toxin-antitoxin systems or an enzymatic active fragment thereof may finally be stored in a buffer.
  • Kits comprising endoribonuclease of the Type III toxin-antitoxin systems
  • compositions and samples of the present invention comprises an endoribonuclease that is not inhibited by the presence of a divalent ion chelator, which is often added to enzyme reactions to stop the catalytic activity of an enzyme.
  • a divalent ion chelator which is often added to enzyme reactions to stop the catalytic activity of an enzyme.
  • the endoribonuclease of the Type III toxin-antitoxin systems therefore have advantageous utility in various molecular biology methods, which involve prior use of other enzymes. Such methods are discussed in more detail below.
  • kits comprising: i) a composition comprising a endoribonuclease of the Type III toxin-antitoxin systems as defined above; and ii) a second composition comprising a second enzyme selecting from a group consisting of a RNA polymerase, a RNA ligase for ligating single stranded RNA molecules, a pyrophosphatase, a phosphatase, a kinase or any other nucleic acid or ribonucleic acid modifying enzymes and at least one further endoribonuclease of the Type III toxin-antitoxin systems with a different recognition site from the endoribonuclease of the Type III toxin-antitoxin systems of i).
  • the second enzyme may be another endoribonuclease of the Type III toxinantitoxin systems having a different recognition site compared to the endoribonuclease of the Type III toxin-antitoxin enzyme as mentioned in i).
  • Kits comprising a endoribonuclease of the Type III toxin-antitoxin systems may comprise a suitable buffer for carry out digestion of RNA.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • the enzymatic activity of the endoribonuclease of the Type III toxin-antitoxin systems makes such enzymes especially suited for use in methods that involves cleavage of single stranded RNA.
  • the different endoribonuclease of the Type III toxin-antitoxin systems cleave single stranded RNA molecules at different recognition sites.
  • composition comprising a endoribonuclease of the Type III toxin-antitoxin systems may be a solution for application to a sample wherein the sample comprising at least one isolated single stranded RNA molecule comprising at least one cleavage site for a endoribonuclease of the Type III toxin-antitoxin systems.
  • a method of cleaving single stranded RNA molecules in a sample comprising the steps: a. providing a sample comprising at least one single stranded RNA molecule comprising at least one cleavage site for a ToxN endoribonuclease; and b. contacting a endoribonuclease of the Type III toxin-antitoxin systems or an enzymatically active fragment thereof with said sample under conditions which permits cleavage of at least a portion of said RNA molecules present in the sample.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • the step of digestion will typically be incubation and is described above and in the examples.
  • Suitable incubation comprises incubation at around 10°C to around 50°C, such as around 10°C to 30°C, preferably around 15°C for 1 minute to about 2 hours, such as from about 5 minutes to about 1.5 hours, such as from about 15 minutes to about 1 hour.
  • the single stranded RNA molecule in the sample may be a concatemer comprising multiple copies of precursors of either mRNA, siRNA, circular RNA, precursors, microRNA or ribozyme and wherein the concatemeric RNA molecule comprises a cleavage site for a ToxN endoribonuclease between each copy of precursors of mRNA, siRNA, circular RNA, microRNA or ribozyme.
  • RNA 5’end and 3 ’end produced by ToxN can be exploited through subjecting the RNA to a RtcB Ligase reaction which ligates 3'-PO4 ends with 5'-OH ends of RNA. By this reaction the RNA becomes circular.
  • RtcB ligases The mechanism of making circular RNA by the use of RtcB ligases is described in Tanaka, N. et al., Novel mechanism of RNA repair by RtcB via sequential 2’, 3’- cyclic phosphodiesterase and 3 ’-phosphate/5’ -hydroxyl ligation reactions, J Biol Chem., 2011, vol.286, no.50, p.43134-43143.
  • RNA molecules comprise a cleavage site for an endoribonuclease of the Type III toxin-antitoxin systems; contacting an endoribonuclease of the Type III toxin-antitoxin systems s with said RNA molecule under conditions that permit digestion of at least a portion of the RNA molecules present in the sample thereby producing RNA molecules comprising 3'-PO4 ends and 5'-OH ends; contacting the digested RNA molecules with RtcB ligase under conditions which permits ligation thereby producing circular RNA.
  • Rolling circle transcription using small circular single-stranded DNA as the template, has been well investigated in the past two decades. Interestingly, transcription via the rolling circle mechanism is achieved by using the T7 RNA polymerase but may happen in absence of the specific canonical promoters and generate transcripts that are tandemly repeated sequences complementary to the circular template.
  • RNase H Wang et al., Preparation of small RNAs using rolling circle transcription and site-specific RNA disconnection, Molecular Therapy -Nucleic Acids, 2015, e215) or ribozymes (W02020023741) are reported.
  • the method is simplified and no longer requires RNase H and a helper DNA fragment or the use of synthetic or in-the-transcript encoded ribozymes.
  • RNA polymerase a method for synthesizing RNA by rolling circle transcription (RCT), as outlined in figure 11.
  • the method comprises the steps: -providing a single stranded DNA plasmid comprising a sequence encoding an RNA recognition site for an endoribonuclease of the Type III toxin-antitoxin systems optionally in proximity of a recognition site (also called promoter) for an RNA polymerase;
  • the RNA polymerase will continue to amplify RNA into long chains with multiple copies of the RNA of interest;
  • RNA is cleaved by ToxN to yield multiple copies of the RNA.
  • This process can be simultaneous with RNA polymerase to constantly produce new RNAs.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • siRNA Small interfering RNA
  • siRNA is a class of double-stranded RNA typically 20-24, normally around 21 base pairs in length, i.e. similar to miRNA.
  • siRNAs operate within the RNA interference (RNAi) pathway and it interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, thereby preventing translation.
  • RNAi RNA interference
  • a method of synthesizing siRNAs comprising the steps: a. providing a sample comprising at least one rolling circle transcribed concatemeric RNA molecule comprising cleavage sites for two different endoribonuclease of the Type III toxin-antitoxin systems, for example endoribonuclease -A and endoribonuclease -B, having different recognition sites, wherein the recognition sites for endoribonuclease -B is situated between tandem repeats and recognition sequences for endoribonuclease -A is situated within the tandem repeats; b.
  • the resulting overhangs containing parts of the endoribonuclease of the Type III toxin-antitoxin systems recognition sites is removed by using a standard singlestrand specific ribonuclease such as RNase T1 thereby producing double stranded siRNAs.
  • RNase T1 a standard singlestrand specific ribonuclease
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • the family of endoribonuclease of the Type III toxin-antitoxin systems are highly useful in RNA analysis in particular of long modified RNA molecules which have to be cleaved into fragments in order to be able to aid the analysis of the RNA modification.
  • the family of endoribonuclease of the Type III toxin-antitoxin systems is a group of enzymes that cleave single stranded RNA at specific recognition sequences without the need of any guide RNA, ribozymes or in complex with DNA probes.
  • capping of synthetically produced mRNA is crucial for an efficient in vivo translation of the mRNA into a functional protein or peptide.
  • capping of RNA in mRNA manufacturing is known to be an incomplete process leaving a portion of the produced mRNA uncapped. Completeness of capping can be assessed by methods such as LC-MS, IP RP HPLC, gel electrophoresis such as PAGE or capillary gel-electrophoresis (CGE).
  • RNA product solution changes the molecular weight of an RNA fragment at a level that is undetectable in standard molecular biology analytics.
  • heterogeneity of an RNA product solution in terms of different product lengths makes it even more difficult to assess a change in molecular weight of the whole RNA population.
  • contemplated length harmonization of the whole RNA population would eventually yield only 2 to 5 sub-populations differing in terms of molecular weight dependent on their capping state.
  • mRNA capping structures are well known to a skilled person and Chan, S.H. et al., RNase H-based analysis of synthetic mRNA 5’cap incorporation, RNA 2022, vol.28, p.l 144-1155 discloses several examples of 5’mRNA capping structures.
  • Chan, S.H. et al. 2022 also discloses analysis of 5’capping efficiency of mRNA using DNA-RNA chimera-guided RNaseH cleavage of newly synthetically produced mRNA.
  • a problem with RNaseH in this method is that it is difficult to get uniform cuts as the reaction has to be optimized both with regard to optimal DNA-RNA hybridization and the enzymes ability to provide a uniform cut.
  • Another advantage with ToxN endoribonucleases is that they only require a pentamer as recognition site.
  • ribozymes instead of RNase H has been suggested, EP3183340, however ribozymes requires excess amount of the enzyme and the enzyme is highly dependent on a 3D-structure of the RNA for cleavage.
  • RNA molecules have been detected in eukaryotes, bacteria and archaea.
  • noncanonical caps are primarily derived from metabolites and cofactors such as NAD + , FAD + among others.
  • the nonconical caps can affect RNA stability, mitochondrial function and RNA translation, Doamekpor et al. 2022 (https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283932/)
  • the inventors have the family of endoribonuclease of the Type III toxin-antitoxin systems can overcome the problem of the endoribonucleases of the prior art, as the enzyme is able to digest single stranded RNA without the need of a hybridized DNA probe, a guide RNA or particular 3D structure of the RNA molecule for RNA cleavage.
  • a method of analyzing the 5’capping efficiency of in vitro transcribed including co- transcriptional 5’capping of mRNA using ToxN enzyme is outlined in figure 9a.
  • the mRNA is in vitro transcribed and includes a recognition site for a ToxN enzyme in the 5’UTR.
  • the endoribonuclease of the Type III toxin-antitoxin systems recognition sequence is placed at a predefined number of ribonucleotides from the 5 ’end of the synthetically transcribed and 5 ’capped mRNA. Digestion of the 5 ’capped RNA with ToxN produced a population of 5’capped mRNA molecules of an equal ribonucleotide length.
  • the molecular weight difference provided by the modification is insignificant in long RNA molecules.
  • RNA molecules are RNA molecules of at least 10, 100, 200, 500 or 1000 nucleotides in length.
  • the RNA molecule has a length from 5 to 50000 nucleotides, 10 to 30000 nucleotides, 100 to 25000 nucleotides or 200 to 20000 nucleotides, 500 to 15000 nucleotides.
  • the 5’capped mRNA fragment generated after digestion with a ToxN enzyme comprises 2 to 100 ribonucleotides, preferably from 5 to 50 ribonucleotides and more preferably from 5 to 10 ribonucleotides.
  • a recognition sequence for a endoribonuclease of the Type III toxin-antitoxin systems may be transcriptionally introduced on each side of a possible RNA fragment in question in order to investigate RNA modifications at internal positions of an RNA molecule.
  • a recognition sequence for a endoribonuclease of the Type III toxin-antitoxin systems may be transcriptionally introduced in front of the Poly(A)-tail of a possible mRNA fragment in question in order to investigate the Poly(A)-tail length distribution of an mRNA molecule.
  • a method of determining 5’capping efficiency of RNA molecule modification comprising the steps: a. providing a sample comprising at least one single stranded mRNA molecule comprising a cleavage site for a endoribonuclease of the Type III toxin-antitoxin systems in the 5’UTR of said mRNA; b. contacting said sample from step a) with a endoribonuclease of the Type III toxin-antitoxin systems or an enzymatic active fragment thereof under conditions that permits cleavage of at least a portion of said single stranded RNA molecules to produce at least one 5’ terminal RNA fragment and at least one 3 ’ terminal RNA fragment. c. separating the RNA fragments from step b) and determine the presence of a 5’- capping modification at the 5 ’end of said 5’ terminal RNA fragment.
  • step c) of the above method is based on different molecular weight, charge or length of the generated RNA fragments.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • a method of determining Poly(A)-tail length distribution of RNA molecules comprising the steps: a. providing a sample comprising at least one single stranded mRNA molecule comprising a cleavage site for a endoribonuclease of the Type III toxinantitoxin systems in the 3’UTR of said mRNA located upstream of the Poly(A)-tail; b.
  • a endoribonuclease of the Type III toxin-antitoxin systems or an enzymatically active fragment thereof under conditions that permits cleavage of at least a portion of said single stranded RNA molecules to produce at least one 5’ terminal RNA fragment and at least one 3’ terminal RNA fragment.
  • the 3’ terminal RNA fragments comprising poly(A)-tails may be enriched by using an oligo-dT based enrichment step thereby removing the non-Poly(A) containing fraction.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • the separation and detection of step c) of the above method is based on different molecular weight, charge or length of the generated RNA fragments.
  • separation and detection of the RNA fragments is selected from gel electrophoresis, capillary electrophoresis, high pressure liquid chromatography (HPLC), mass spectrometry (MS) or LC-MS, LC-UV.
  • HPLC high pressure liquid chromatography
  • MS mass spectrometry
  • LC-MS LC-UV
  • capping analysis after cleavage with an endoribonuclease of the Type III toxin-antitoxin systems can be performed the same way as the other methods with LC-MS, FFF (Fastflow Fractionation) or similar techniques.
  • the pentamer recognition site is quite versatile and can be placed anywhere in the 5’UTR.
  • the enzyme does not require an overhang and cuts ssRNA that starts with the cleavage sites.
  • the analysis can be done on a simple urea/acrylamide gel.
  • Example lOa-c and figure 9b-d shows that the endoribonuclease of the Type III toxin-antitoxin systems may be used in a method for analysing RNA modifications such as for example 5’ capping of RNA.
  • RNA restriction enzymes may be used to exploit the different location of cleavage sites in a ssRNA.
  • RNA fingerprinting is an important tool within diagnostics and therapeutics, endoribonuclease of the Type III toxin-antitoxin systems for use in analytically RNA fingerprinting has several advantages including a fast and reliable fragmentation of single stranded RNA molecules of defined length that can be analysed by gel electrophoresis, capillary electrophoresis, high pressure liquid chromatography (HPLC), mass spectrometry (MS) or LC-MS, LC-UV.
  • HPLC high pressure liquid chromatography
  • MS mass spectrometry
  • LC-MS LC-MS
  • RNA fingerprinting illustrated in figure 10a, wherein the method comprises the steps: a. providing a sample comprising a single stranded RNA molecule with unknown sequence; b. contacting said sample from step a) with a endoribonuclease of the Type III toxin-antitoxin systems or an enzymatic active fragment thereof under conditions that permit cleavage of at least a portion of the RNA molecules present in said sample obtaining a plurality of RNA fragments; c. separation and detection of the fragmented RNA molecules from step b) thereby obtaining a fingerprint of said RNA molecule with unknown sequence and compare the obtained fingerprint with fingerprints from RNA molecules with known RNA sequence.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • RNA fingerprinting method Determination of RNA species within a multivalent RNA composition as described in WO2022212711, is another RNA fingerprinting method wherein the use of a ToxN endoribonuclease will simplify and improve the method over RNase H enzymes that require a hybridized DNA probes at their recognition site.
  • the method is based on RNA compositions comprising one or more distinct RNA species (e.g, RNAs encoding different proteins), where each RNA species comprises a unique nucleotide sequence that can be used to identify the RNA species.
  • RNA compositions comprising one or more distinct RNA species (e.g, RNAs encoding different proteins), where each RNA species comprises a unique nucleotide sequence that can be used to identify the RNA species.
  • IDR ratio determination
  • RNAs can be digested to release RNA fragments comprising the IDR sequence, and analytical methods can be used to quantify the types and amounts of RNA fragments containing each IDR, to generate a profile of the types and/or amounts of each RNA species in a RNA composition.
  • IDR sequences for analysis allows characterization of multivalent RNA compositions comprising several distinct RNA species, even if multiple RNA species are difficult to distinguish by length or coding sequence.
  • a multivalent RNA composition comprising eight RNA species, each encoding a different serotype of the same protein, may have similar lengths and coding sequences, but each RNA species may comprise a different IDR pattern in a coding or non-coding region. Because each IDR sequence unambiguously identifies a particular RNA species, the abundance of IDR sequences may be measured to determine the abundance of RNAs encoding each serotype.
  • coding sequence of one or more RNA species in a multivalent RNA composition may be modified (e.g., to alter the structure of an encoded therapeutic protein or antigen) independently from the IDR sequence, such that the same analytical methods may be used to evaluate a RNA composition in which one or more RNA coding sequences are modified.
  • a method for analysing a RNA species in a multivalent RNA composition comprising the steps: a. providing a sample comprising a multivalent RNA composition comprising a first RNA species and a second RNA species comprising a cleavage site for a endoribonuclease of the Type III toxin-antitoxin systems in at least one position of said first RNA species and a second RNA species; b.
  • the RNA molecule may be selected from mRNA, viral RNA, invitro transcribed mRNA, therapeutic RNA.
  • the endoribonuclease of the Type III toxin-antitoxin systems are the CptN endoribonucleases or TenpN endoribonucleases as defined above.
  • RNA digestion buffers Suitable RNA digestion buffers and reaction conditions for carry out cleavage of RNA is described in detail above.
  • step c) of the above method may be based on different molecular weight, charge or length of the generated RNA fragments.
  • separation and detection of the RNA fragments is selected from gel electrophoresis, capillary electrophoresis, high pressure liquid chromatography (HPLC), mass spectrometry (MS) or LC-MS, LC-UV.
  • HPLC high pressure liquid chromatography
  • MS mass spectrometry
  • LC-MS LC-UV
  • Example 11 and figures 10b and 10c shows that endoribonucleases from Type III toxin-antitoxin (TA) system such as endoribonucleases from the ToxN subfamily may be used in a method for RNA fingerprinting.
  • Figure 10b depicts two synthetic RNA oligoes of identical length of 20 bases that migrate equally in the urea/acrylamide gel (lanes 1 and 8). However, each RNA oligo has the E.coli ToxNl (ET-N1) cleavage site located at different position in the RNA sequence. Thereby, the RNA molecules present in the mixture can be identified by their unique pattern of RNA fragments. Furthermore, the band intensity can be used to estimate the ratio of the two RNA molecules in the mixture, cf. figure 10c.
  • E.coli ToxNl E.coli ToxNl
  • coli BL21(DE3) cells and grown overnight at 37°C, 180 rpm, followed by the secondary culture at 37°C, 180 rpm till OD600 ⁇ 0.5.
  • the culture was incubated at 15°C without shaking for 30 min and the toxin was induced by adding IPTG to a final concentration of 1 mM and incubated at 15°C, 180 rpm for 24 h.
  • the cells were harvested by centrifugation at 6000 rpm for 15 min.
  • the cells were resuspended in lysis buffer (50 mM Tris, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 2 mM 2-mercaptoethanol pH 7.5 at 25°C) and lysed by sonication.
  • lysis buffer 50 mM Tris, 300 mM NaCl, 10 mM imidazole, 10% glycerol, 2 mM 2-mercaptoethanol pH 7.5 at 25°C
  • the lysate was centrifuged at 13 000 rpm for 30 min, and the supernatant was loaded on a Ni 2+ -NTA column.
  • the complex was eluted using elution buffer (lysis buffer + 200 mM imidazole).
  • Fractions containing the complex were dialyzed against ion-exchange buffer (50 mM NaCl, 50 mM Tris-HCl, 1 mM DTT pH 7.5) and purified using anion exchange chromatography by increasing gradient of NaCl from 50 to 1000 mM, over a volume of 100 ml, which yielded separate fractions of toxin, -E.coli ToxNl (ET-N1) (at ⁇ 300 mM NaCl), antitoxin, RNA (at ⁇ 600 mM NaCl) and complex of E.coli ToxNl-RNA (at ⁇ 500 mM NaCl). They were further purified by size exclusion chromatography (SEC) using an S200 column (GE).
  • SEC size exclusion chromatography
  • Toxin E . coli ToxNl
  • Toxin E . coli ToxNl
  • Example 2 in vitro transcription and production of RNA oligoes comprising a ToxN recognition and cleavage site
  • In vitro transcription was done in 50 pL reactions with 30U T7 RNA Polymerase (ThermoSci entific, EP0111) using the included 5X reaction buffer (200 mM Tris- HC1 pH 7.9; 30 mM MgC12, 50 mM DTT, 50 mM NaCl, 10 mM spermidine), 50U RiboLock RNase Inhibitor (ThermoScientific, EO0381), 2 mM NTPs (ThermoScientific, R1481), and 1 pg linearized (Seal digested) pGEMEX-1 template.
  • 5X reaction buffer 200 mM Tris- HC1 pH 7.9; 30 mM MgC12, 50 mM DTT, 50 mM NaCl, 10 mM spermidine
  • 50U RiboLock RNase Inhibitor ThermoScientific, EO0381
  • 2 mM NTPs
  • any linearized plasmids with a T7 promoter and ToxN cleavage sites or PCR products including a T7 promoter and ToxN cleavage sites can be used.
  • the transcription reaction lasted for 2h at 37°C and was inactivated by adding 10 pL 60 mM ETDA followed by a 10 min incubation at 65°C. Reaction cleanup was conducted using the RNeasy MiniElute Cleanup Kit (Qiagen, 74204) to elute the purified RNA in RNase free water.
  • E.coli ToxN GAA A AU
  • B. Thuringiensis ToxN (BT-N1): AAA A AAA
  • Escherichia albertii ToxN/AbiQ (ET-N5): 5’..GAAAj,AAC..3’ and 5’.
  • the experiment was performed in order to verify that the E.coli ToxNl (NCBI Acc. No.: WP 059274511) of use according to the invention exhibit endoribonuclease activity on a single-stranded RNA substrate.
  • Example 4 Activity profiling of E.coli ToxNl (ET-N1) endoribonucleases: concentration of monovalent salt and pH
  • RNA single strand oligo Digestion of a 50 nucleotide RNA single strand oligo with ToxN.
  • the recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3).
  • the results are shown in figure 3 and demonstrates that the ToxN enzyme are able to cleave single stranded RNA at pH ranging from 7.0 to 9.0.
  • the results further demonstrate that the specificity of the enzyme is dependent on monovalent ion concentration and is optimal at NaCl concentrations of 50 mM and lower. Above 50 mM the cleavage of the RNA is less specific and the enzyme digests RNA at secondary closely related sequence recognition sites.
  • Example 5 Activity profiling of ToxN endoribonucleases: concentration of divalent salt a) Digestion of a 50 nucleotide RNA single strand oligo with E.coli ToxNl (ET-N1). The recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3). The results are shown in figure 4a. E.coli ToxNl (ET-N1) enzyme activity is extensively inhibited by concentrations of MgCh above ImM (lane E - lane J).
  • Example 6 Activity profiling of E.coli ToxNl (ET-N1) endoribonucleases: concentration of divalent salt, EDTA and DTT
  • RNA single strand oligo Digestion of a 50 nucleotide RNA single strand oligo with ToxNl recognition sequence.
  • the recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3).
  • Example 7 Activity profiling of E.coli ToxNl (ET-N1) endoribonucleases: incubation time at 15°C
  • RNA single strand oligo Digestion of a 50 nucleotide RNA single strand oligo with E.coli ToxNl (ET-Nl)at increasing incubation time.
  • the recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3).
  • the results are shown in figure 6 and demonstrates that the enzyme is efficient. 50% of the RNA oligos are cleaved after 5 min at an optimal assay temperature of 15°C (lane C).
  • Example 8 Activity profiling of ToxN endoribonucleases: incubation temperature
  • the recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3).
  • the aim of the study was to profile the enzyme activity at different incubation temperatures. The results are shown in figure 7.
  • RNA single strand oligo Digestion of a 50 nucleotide RNA single strand oligo with E.coli ToxNl (ET-N1).
  • the recognition site GAAAU is in the centre of the oligo and results in a product of 26 nucleotides (the sequence of the oligo is shown in Example 3).
  • the aim of the study was to profile the enzyme activity at different incubation temperatures. The results are shown in figure 8 and demonstrates that the enzyme specificity decreases at temperatures above 30°C.
  • IVTT In vitro translation
  • IVT RNA Digestion of the IVT RNA was performed at 37 °C. After stopping the IVT reaction with EDTA, a fraction of the IVT reaction was mixed with 10-90 nM E.coli ToxNl (ET-N1) for 10-20 min in IVT buffer. The reaction was stopped by adding urea gel loading buffer (95% Formamide, 0.25 M EDTA, Bromophenol blue) and the samples loaded on a 20 % urea/acrylamide gel. The samples were visualized with SYBRGold.
  • E.coli ToxNl E.coli ToxNl
  • Example 10b Analysis of Post -transcriptional Capping efficiency of mRNA pGEM3Zf-ETNl + 13 was linearized with HincII and used in a T7 RNAP IVT reaction. Half of the resulting GEM3Zf mRNA was then capped using a vaccinia capping enzyme and purified on a silica column. Next, half of the capped and uncapped mRNA was digested using the E.coli ToxNl (ET-N1) endoribonuclease and loaded on a 10% polyacrylamide gel containing 7M urea (TBE, Sybr Gold).
  • E.coli ToxNl E.coli ToxNl
  • TBE Sybr Gold
  • FIJI was used to quantify the relative band intensity of capped ( « pl) and uncapped (p2) mRNA fragments (averaged peak heights of three slices, indicated as “a, b, c” for capped mRNA and “d, e, f’ for uncapped mRNA).
  • About 150 ng mRNA was loaded per lane after 1 : 1 dilution in RNA loading buffer and heating 10 minutes at 65°C.
  • the results from the analysis of 5 ’-cap status is depicted in figure 9c. This method indicates that 56% of the mRNA is capped.
  • Example 10c - Analysis of co-transcriptional capping efficiency of mRNA pAZ Ol was linearized with PpuMI and used in a T7 RNAP IVT reaction with and without co-transcriptional capping with cap analogs.
  • Half of the capped and uncapped pAZ_01 mRNA was digested using the E.coli ToxNl (ET-N1) endoribonuclease and loaded on a 10% polyacrylamide gel containing 7M urea (stained with Sybr Gold). Uncapped mRNA and capped mRNA that was digested with ET-N1 shows one band of larger size thereby suggesting near to 100% capping efficiency.
  • About 150 ng mRNA or 15 ng RNA oligos were loaded per lane after 1 : 1 dilution in RNA loading buffer and heating 10 minutes at 65°C.
  • RNA Fingerprinting by digestion of two 20 nucleotide RNA substrates simultaneously (MOD-UTR: GGGAAJ.AUAAGAGAGAAAAGA-FAM and Distl : GCCGAA AUAGUGACCCUGCA-FAM).
  • the FAM labelled products differ by just one nucleotide resulting in product band of 15 and 14 nucleotides respectively. Reaction conditions: 10 min at 37 °C with 10 nM E.coli ToxNl (ET-N1), 500 nM substrate. Only the product with the FAM label is visible.
  • FIG. 10b The results from the fingerprint analysis is depicted in figure 10b.
  • Figure 10c depicts the ratio of the two RNA molecules in the mixture calculated by measuring the band intensities.
  • Mango aptamer production An IVT produced concatemer of the Mango aptamer was digested with E.coli ToxNl (ET-N1), at decreasing enzyme concentrations in a buffer comprising 25 mM Tris/HCl, 25 mM NaCl pH 7.5, for 20 min at 37 degrees Celsius.
  • E.coli ToxNl E.coli ToxN1
  • the Mango aptamer is described in Dolgosheina et al., 2014; doi: 10.1021/cb500499x.
  • Example 13 stability of the E.coli ToxNl (ET-N1) enzyme in the presence of monovalent salt in the storage buffer 100 mm NaCl to 500 mM NaCl.
  • Example 14 Digestion of RNA by other ToxN endoribonucleases of the ToxIN family
  • BT-N1 recognizes and cleaves with good confidence AAAJ.AAA.
  • ET-N5 cleaves GAAAJ.AAC and AAAAJ.AUC with similar efficiency.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne des compositions comprenant une endoribonucléase spécifique de séquence et des procédés d'utilisation de celles-ci dans l'analyse d'ARN, la synthèse d'ARN et l'empreinte digitale de molécules d'ARN. En particulier, la présente invention concerne des compositions et des échantillons comprenant une endoribonucléase isolée de systèmes toxine-antitoxine de type III, de préférence des endoribonucléases de la sous-famille CptN et de la sous-famille TenpN.
PCT/EP2024/053112 2024-02-07 2024-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation Pending WO2025168209A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/EP2024/053112 WO2025168209A1 (fr) 2024-02-07 2024-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation
PCT/EP2025/053315 WO2025168812A1 (fr) 2024-02-07 2025-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2024/053112 WO2025168209A1 (fr) 2024-02-07 2024-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation

Publications (1)

Publication Number Publication Date
WO2025168209A1 true WO2025168209A1 (fr) 2025-08-14

Family

ID=89897340

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP2024/053112 Pending WO2025168209A1 (fr) 2024-02-07 2024-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation
PCT/EP2025/053315 Pending WO2025168812A1 (fr) 2024-02-07 2025-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/EP2025/053315 Pending WO2025168812A1 (fr) 2024-02-07 2025-02-07 Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation

Country Status (1)

Country Link
WO (2) WO2025168209A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101416A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Procédés d'analyse d'arn
EP3183340A1 (fr) 2014-08-19 2017-06-28 Arcticzymes AS Exonucléases thermolabiles
AU2016297778A1 (en) 2015-07-24 2018-03-15 The Johns Hopkins University Compositions and methods of RNA analysis
WO2020023741A1 (fr) 2018-07-25 2020-01-30 Ohio State Innovation Foundation Production à grande échelle de particules d'arn
WO2022212711A2 (fr) 2021-04-01 2022-10-06 Modernatx, Inc. Procédés d'identification et de détermination de rapport d'espèces d'arn dans des compositions d'arn multivalentes

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015101416A1 (fr) 2013-12-30 2015-07-09 Curevac Gmbh Procédés d'analyse d'arn
EP3183340A1 (fr) 2014-08-19 2017-06-28 Arcticzymes AS Exonucléases thermolabiles
AU2016297778A1 (en) 2015-07-24 2018-03-15 The Johns Hopkins University Compositions and methods of RNA analysis
WO2020023741A1 (fr) 2018-07-25 2020-01-30 Ohio State Innovation Foundation Production à grande échelle de particules d'arn
WO2022212711A2 (fr) 2021-04-01 2022-10-06 Modernatx, Inc. Procédés d'identification et de détermination de rapport d'espèces d'arn dans des compositions d'arn multivalentes

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
BLOWER TIM R ET AL: "A processed noncoding RNA regulates an altruistic bacterial antiviral system", NATURE STRUCTURAL & MOLECULAR BIOLOGY, vol. 18, no. 2, 16 January 2011 (2011-01-16), New York, pages 185 - 190, XP093189849, ISSN: 1545-9993, DOI: 10.1038/nsmb.1981 *
BLOWER, T.R. ET AL.: "identification and classification of bacterial Type III toxin-antitoxin systems encoding in chromosomal and plasmid genomes", NUCLEIC ACID RESEARCH, vol. 40, no. 13, 2012, pages 6158 - 6173
CHAN, S.H. ET AL.: "RNase H-based analysis of synthetic mRNA 5'cap incorporation", RNA, vol. 28, 2022, pages 1144 - 1155
GAWIN, A. ET AL.: "The XylS/Pm regulator/promoter system and its use in fundamental studies of bacterial gene expression, recombinant protein production and metabolic engineering", MICROB. BIOTECHNOL., vol. 10, no. 4, 2017, pages 702 - 718, XP055753979, DOI: 10.1111/1751-7915.12701
GUEGLER CHANTAL K ET AL: "A phage-encoded RNA-binding protein inhibits the antiviral activity of a toxin-antitoxin system", NUCLEIC ACIDS RESEARCH, vol. 52, no. 3, 20 December 2023 (2023-12-20), GB, pages 1298 - 1312, XP093189932, ISSN: 0305-1048, DOI: 10.1093/nar/gkad1207 *
GUEGLER CHANTAL K. ET AL: "Shutoff of host transcription triggers a toxin-antitoxin system to cleave phage RNA and abort infection", MOLECULAR CELL, vol. 81, no. 11, 1 June 2021 (2021-06-01), AMSTERDAM, NL, pages 2361 - 2373.e9, XP093058945, ISSN: 1097-2765, DOI: 10.1016/j.molcel.2021.03.027 *
HANSEN LHKNUDSEN SSORENSEN SJ: "The effect of the lacY gene on the induction of IPTG inducible promoters, studied in Escherichia coli and Pseudomonas fluorescens", CURR. MICROBIOL., vol. 36, no. 6, 1998, pages 341 - 7
HENGESBACH, M. ET AL.: "Use of DNAzymes for site-specific analysis of ribonucleotide modification", RNA, vol. 14, no. 1, 2008, pages 180 - 187
MANIKANDAN PARTHASARATHY ET AL: "Identification, functional characterization, assembly and structure of ToxIN type III toxin-antitoxin complex from E. coli", NUCLEIC ACIDS RESEARCH, vol. 50, no. 3, 22 February 2022 (2022-02-22), GB, pages 1687 - 1700, XP093189859, ISSN: 0305-1048, DOI: 10.1093/nar/gkab1264 *
MANIKANDAN, P. ET AL.: "Identification, functional characterization, assembly and structure of ToxIN type III toxin-antitoxin complex from E.coli", NUCLEIC ACID RESEARCH, vol. 50, no. 3, 2022, pages 1687 - 1700
RAAB, D.GRAF, M.NOTKA, F.SCHBDL, T.WAGNER, R.: "The GeneOptimizer Algorithm: Using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization.", SYSTEMS AND SYNTHETIC BIOLOGY, vol. 4, no. 3, 2010, pages 215 - 225, XP055065511, DOI: 10.1007/s11693-010-9062-3
RAO FENG ET AL: "Co-evolution of quaternary organization and novel RNA tertiary interactions revealed in the crystal structure of a bacterial protein-RNA toxin-antitoxin system", NUCLEIC ACIDS RESEARCH, vol. 43, no. 19, 8 September 2015 (2015-09-08), GB, pages 9529 - 9540, XP093189880, ISSN: 0305-1048, DOI: 10.1093/nar/gkv868 *
SHORT FRANCESCA L. ET AL: "Selectivity and self-assembly in the control of a bacterial toxin by an antitoxic noncoding RNA pseudoknot", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 110, no. 3, 24 December 2012 (2012-12-24), XP093189834, ISSN: 0027-8424, DOI: 10.1073/pnas.1216039110 *
TANAKA, N. ET AL.: "Novel mechanism of RNA repair by RtcB via sequential 2', 3'-cyclic phosphodiesterase and 3'-phosphate/5'-hydroxyl ligation reactions", J BIOL CHEM., vol. 286, no. 50, 2011, pages 43134 - 43143, XP055063977, DOI: 10.1074/jbc.M111.302133
VLATKOVIC ET AL.: "Ribozyme assays for quantifying the capping efficiency of in vitro transcribed mRNA", PHARMACEUTICS, vol. 14, no. 2, 2022, pages 328
WANG ET AL.: "Preparation of small RNAs using rolling circle transcription and site-specific RNA disconnection", MOLECULAR THERAPY -NUCLEIC ACIDS, 2015, pages e215

Also Published As

Publication number Publication date
WO2025168812A1 (fr) 2025-08-14

Similar Documents

Publication Publication Date Title
AU2017295602B2 (en) Novel processes for the production of oligonucleotides
EP3728585B1 (fr) Nouveaux procédés de production d'oligonucléotides
HK1203218A1 (en) Use of template switching for dna synthesis
EP4582542A1 (fr) Procédé de préparation d'un oligonucléotide à l'aide d'une arn ligase
US9353358B2 (en) Sequence-specific engineered ribonuclease H and the method for determining the sequence preference of DNA-RNA hybrid binding proteins
CN115820604A (zh) 一种高温Argonaute蛋白质及其应用
EP1539945B1 (fr) Endonucleases de restriction recombinantes de type ii, mmei, endonucleases associees et procedes de production correspondants
WO2025168209A1 (fr) Compositions comprenant une endoribonucléase spécifique de séquence et procédés d'utilisation
WO2024165645A1 (fr) Compositions comprenant une endoribonucléase séquence-spécifique et procédés d'utilisation
Fukuda et al. Roles of TraI protein with activities of cleaving and rejoining the single‐stranded DNA in both initiation and termination of conjugal DNA transfer
US20240043907A1 (en) Mrna analysis using restriction enzymes
US20230125232A1 (en) Atp-dependent dna ligase
Martínez-Carrón et al. Methods of amplifying template nucleic acid using a thermostable Tthprimpol
CN120608036A (zh) 热稳定单链dna/rna连接酶及其应用
WO2025214320A1 (fr) Procédé d'amplification d'acide nucléique cible et kit correspondant
JP2022551588A (ja) Ｄｎａポリメラーゼおよびｄｎａポリメラーゼ由来３’－５’エキソヌクレアーゼ
WO2015185534A1 (fr) Enzymes désoxyribonucléases améliorées
CN116391042A (zh) Dna组装混合物和其使用方法
US20140308711A1 (en) Enzymatic phosphorothioation of dna or rna
Nathania Biochemical analysis of Thermotoga maritima ribonuclease III and its ribosomal RNA substrates
Evers Undergraduate Honors Program Chemistry Isolation and Amplification of the strK gene of Streptomyces griseus: A look at a specific phosphatase
JP2010088446A (ja) 新規ｄｎａ分解酵素
JP2014221028A (ja) 二本鎖デオキシリボ核酸にニックを導入する方法及びニッキング酵素活性を有するタンパク質

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 24704155

Country of ref document: EP

Kind code of ref document: A1